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Tumor samples are available from over 19,600 Stage I-III breast cancer patients treated according to evolving British
Columbia guidelines from 1978 to 1990. A tissue mico-array (TMA) was constructed from 930 of these patients, all of
whom participated in randomized or phase II studies. Outcome was defined as 20-year Breast Cancer specific Survival
(BrCaSS), with events defined as Breast Ca death. Follow up was median 17.8 years (ranges 11–28). Multiple tumor
markers were tested, and results correlated with 20-year BrCaSS for markers expressed versus non-expressed.
20-year BrCaSS
Marker Expressed (%) Not expressed (%) p-Value
Her-2-IHC 34 48 <0.0001
Her-2 FISH 33 48 0.0004
Her-2 ACIS IHC∗∗ 32 47 0.0001
Cytokeratins 17/5,6 IHC: 35 47 <0.0020
uPA IHC 46 52 0.0300
Cox-2 IHC 32 45 0.0260
No difference in BrCaSS was found for aromatase, integrin-linked kinase (ILK), IGF-1 and Topo-isomerase-2. The
negative predictive value of IHC versus FISH and ACIS-IHC versus FISH was 96 and 97%, respectively. The positive
predictive value of IHC versus FISH and ACIS-IHC versus FISH was 84 and 84%, respectively. All tests, with the
exception of HER-2 FISH were done by IHC. Results of other markers (VEGF, ER/PgR, hypoxia markers, etc.), and an
interactive multivariate analysis adjusting for conventional prognostic factors and for all above markers, are in progress.
Conclusions 1. The TMA is a technique which provides opportunity for rapid screening of multiple genetic markers.
2. Expression of Her-2/Neu, uPA, Cox-2 and Cytokeratin 17/5,6 (but not of Aromatase, ILK, TOPO-II and IGF-1)
is associated with inferior BrCaSS. 3. HER-2 determination by ACIS-IHC provides comparable results to IHC done
manually (with a potential for more uniform reporting), and both provide comparable results to Her-2 assessment by
FISH. ∗∗ACIS-IHC:IHC red by Automated Cell Image System (M.L.)
